Driving Pathology Forward: Instem Strengthens Provantis ® with Continued Investment and Innovation
Deep Digital Integration
Provantis Pathology now offers enhanced support for digital pathology, allowing users to move effortlessly between Provantis data entry and external applications or data sources. A key highlight is the new, seamless integration with PathcoreFlow™, the powerful digital slide management system from Instem's strategic partner, Pathcore ®.
This integration bridges study management and high-resolution digital slide review, resulting in a more connected, consistent, and efficient pathology workflow. The connection - and its time-saving benefits - is now available for pathologists to implement in their research.
'Digital pathology is no longer a niche - it's a vital foundation for faster, more reliable preclinical insights,' said Charuta Bapat, Director of Product - Study Management at Instem. 'With the latest updates to our Provantis Pathology module and the upcoming release of Provantis 12, we're delivering the most advanced tools designed to help pathologists work more efficiently and with greater confidence.'
'We're incredibly proud of what this integration represents - a fully connected, digitally forward workflow for today's pathology professionals,' said Carlos Frade, Senior Director of Product Knowledge and Business Development at Instem. 'This is a huge step forward for our study management solutions, and we're excited to meet with Pathologists at STP to showcase everything Provantis can do.'
Instem's commitment to a more flexible, future-ready environment is further reinforced by Provantis' growing suite of APIs connecting to 19 different data domains. This includes enhanced Pathology APIs for smoother integration with digital platforms, along with Preclinical Libraries and Studies APIs to extend data interoperability.
Looking ahead in 2025, the upcoming Provantis 12 release will lay the groundwork for a new, non-GLP pathology solution. This module will enable more pathologists to integrate with the Provantis ecosystem - supporting protocol definition, necropsy, and reporting - and empowering pathology teams to work smarter and faster with minimal disruption.
Live Demonstrations at STP 2025
Instem's pathology team will be demonstrating these new features live at the STP Annual Symposium in Chicago, exploring:
New editing capabilities in the histopathology matrix, as part of the upcoming non-GLP pathology module.
A new integration in this module with smart glossaries for simplified terminology management.
How to get started with the Provantis and PathcoreFlow™ integration
These advancements are part of Instem's broader roadmap focused on efficiency, scalability, and comprehensive study support for your lab team.
For details on how Provantis is transforming digital pathology visit www.instem.com/study-management-spotlight-provantis-pathology. To schedule a live demo during or after the STP conference in Chicago, contact info@instem.com.
About Instem
Instem is a leading supplier of SaaS platforms across Discovery, Study Management, Regulatory Submission and Clinical Trial Analytics. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Founded in the United Kingdom in 1969, Instem has deep roots internationally across North America, EMEA, and APAC. Instem maintains a commercial and technical presence throughout these regions and prides itself on localized support for its diverse client base.
About Pathcore
Pathcore ® is dedicated to advancing digital pathology through innovative software solutions that empower organizations with the tools they need to implement digital transformations. For over two decades, our co-founders have led and developed widely used platforms including PathcoreFlow™, the Sedeen Viewer™, and PathcoreScholar™.
Our applications support a wide range of clients in more than 68 countries and 2000 organizations, making data easily accessible and driving the adoption of digital pathology.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
an hour ago
- Boston Globe
SharkNinja rolls into Hollywood spotlight in latest Brad Pitt movie
SharkNinja hosted a 'consumer activation' in New York's Times Square ahead of the city's official premiere, with product demo stations, where passersby could try a Ninja Slushi or a Shark FlexStyle hair styler. Advertisement SharkNinja's Limited-Edition APXGP Performance Collection, as featured in Apple Original Films' F1® The Movie The company hopes to show its ethos around 'design, speed and performance' is reflected in the movie's storyline. For example, chief executive Mark Barrocas said that like 'the characters in the film, we're always pushing to do more, do better, and defy expectations.' Advertisement Spokesman Brandon Hart declined to say how much the company is spending on the movie appearances. Also unclear: how that amount compares with what the company would have to spend to sponsor a real F1 team. This is an installment of our weekly Bold Types column about the movers and shakers on Boston's business scene. Jon Chesto can be reached at
Business Upturn
5 hours ago
- Business Upturn
India's services sector growth hits 10-month high in June as demand strengthens
By Aditya Bhagchandani Published on July 3, 2025, 10:49 IST India's services sector saw robust expansion in June 2025, with business activity rising at its fastest pace in 10 months, driven by strong domestic demand and improving export orders. The HSBC India Services PMI® Business Activity Index climbed to 60.4, up from 58.8 in May, according to the latest survey by S&P Global. A reading above 50 indicates expansion. Service providers reported the sharpest rise in new orders since August 2024, supported by solid growth in both domestic and international markets, particularly from Asia, the Middle East, and the US. Notably, the pace of export growth was among the strongest since records began, though slightly lower than in previous months. Price pressures continued to ease, with input and output price inflation softening to a 10-month low. Employment in the sector grew for the 37th consecutive month, although the pace of job creation moderated from May's record levels. Finance & Insurance led sectoral growth in June, while Real Estate & Business Services lagged behind. On the outlook, service providers remained optimistic about future growth, though overall confidence dipped slightly compared to previous months. Key highlights: Business Activity Index rose to 60.4 in June (58.8 in May) New orders increased at the fastest rate in nearly a year Export orders strong, despite a slight slowdown from May Input cost inflation at a 10-month low; firms maintained pricing power Job creation continues, though at a slower pace Finance & Insurance sector remains the top performer According to Pranjul Bhandari, Chief India Economist at HSBC: 'The Services PMI business activity index was up to a ten-month high, led by a sharp rise in new domestic orders. Margins improved as the rise in input costs was below that seen for output charges.' The data reflects broad-based resilience in India's private sector, with the HSBC India Composite PMI Output Index — combining manufacturing and services — also reaching a 14-month high of 61.0 in June. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Wire
6 hours ago
- Business Wire
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan
BAAR, Switzerland & OSAKA, Japan & TOKYO--(BUSINESS WIRE)--Stallergenes Greer, Shionogi & Co., Ltd. ('Shionogi') and CEOLIA Pharma Co. Ltd ('CEOLIA') today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer's sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis. After ending the license agreement established in 2010 with Shionogi, which had been responsible for developing, registering, and commercialising Actair® in Japan, Stallergenes Greer has appointed CEOLIA as its new promotional partner in the country starting July 3. To ensure the continuity of both patient care and support for healthcare professionals, Shionogi will continue during a transition period to serve as the Marketing Authorisation Holder (MAH) in Japan and remain responsible for the importation, manufacturing and distribution of Actair®. Shionogi will also provide active support to CEOLIA by transferring knowledge and offering operational assistance. Stallergenes Greer acknowledges Shionogi's contribution and sustained commitment to improving allergy care in Japan. The company welcomes CEOLIA as a trusted new partner and looks forward to working closely together to further advance access to allergen immunotherapy treatments and continue to improve the quality of life of patients with respiratory allergies. ABOUT STALLERGENES GREER Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit ABOUT SHIONOGI & Co. Ltd Shionogi has identified 'Contributing to a Healthy and Prosperous Life' as one of its key material issues. The group is committed to building a society where everyone can live vibrantly and true to themselves. With a continued focus on areas of high unmet medical needs, Shionogi strives to deliver innovative treatments that improve the quality of life (QOL) for patients and their families. For more information, visit ABOUT CEOLIA CEOLIA, founded in 2010, is a pharmaceutical company dedicated to serving all healthcare needs in the otolaryngology (ENT) field. With a mission and philosophy to serve and contribute to people's health and happiness, we develop and manufacture and market ethical drugs, medical devices, and diagnostic reagents in the ENT field. For more information, visit
